Muenter M D, Ahlskog J E, Bell G, McManis P
Mayo Clinic Scottsdale, AZ 85259.
Neurology. 1988 Oct;38(10):1541-5. doi: 10.1212/wnl.38.10.1541.
PHNO [(+)-4-propyl-9-hydroxynaphthoxazine] is a chemically novel and highly potent dopamine (D2) receptor agonist without D1 activity. It had significant antiparkinsonism effects when used as open-label monotherapy in ten patients who were Hoehn and Yahr stage 2 or 3. The standard formulation of PHNO produced a 3- to 4-hour therapeutic effect in most patients; the response to the time-release formulation lasted up to 10 hours. Side effects were similar to those of other dopamine agonists but dyskinesia was seen in only one patient.
PHNO [（+）-4-丙基-9-羟基萘并恶嗪]是一种化学结构新颖且强效的多巴胺（D2）受体激动剂，无D1活性。在10例Hoehn和Yahr 2期或3期患者中，作为开放标签单一疗法使用时，它具有显著的抗震颤麻痹作用。PHNO的标准制剂在大多数患者中产生3至4小时的治疗效果；对缓释制剂的反应持续长达10小时。副作用与其他多巴胺激动剂相似，但仅1例患者出现运动障碍。
